Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
A Phase 3 Panorama study in generalized anxiety disorder (GAD) reported that DT120 ODT 100 mcg met all primary and key secondary endpoints, with favorable safety and sustained efficacy in interim extension data (partial).
Definium Therapeutics announces topline results from its Phase 3 Emerge study, meeting primary and key secondary efficacy endpoints for DT120 in major depressive disorder